Recordati Rare Diseases and the FarmaMondo Group sign a new exclusive agreement for three RRD’s rare disease therapies in Hong Kong

Recordati Rare Diseases appoints the FarmaMondo Group as the exclusive commercial partner for its orphan therapies Cosmegen®, Pedea® and Carbaglu® in Hong Kong.

Under the agreement FarmaMondo will serve as a Marketing Authorization Holder in the territory and will provide full commercialization services.

We are proud to have gained such trust from Recordati Rare Diseases, bringing more hope for patients through our growing APAC infrastructure.


FarmaMondo is a fast-growing Swiss group dedicated to providing Biopharma, healthcare professionals and their patients around the world with greater access to medicines, and in the process increasing the value of a pharmaceutical product by extending and expanding its lifecycle. The Group offers high value market access and specialty distribution services, through a unique infrastructure and geographical footprint, targeted to enable patient access to Specialty Medicines in key Emerging Markets through a combined approach of Named Patient access and full commercialization.

For more information about FarmaMondo please visit:



Recordati Rare Diseases, is focused on providing the most effective treatment for people living with rare diseases, forming part of the Recordati Group – a public international specialty pharmaceutical company dedicated to the research, development, manufacturing and marketing of medicines which improve the lives of patients and their families. At Recordati Rare Diseases, we focus on the few, with a mission to reduce the impact of rare and devastating diseases by providing urgently needed therapies.


For more information about Recordati Rare Disease please visit: